drug · protein
evorpacept
Phase 3updated 3mo agoby $ALXO ALX ONCOLOGY HOLDINGS INC🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Phase 2 3 (across all indications), with 5 investigational indications.
targets
Leukocyte surface antigen CD47
all catalysts(0)
nothing on the calendar yet
Trials studying evorpacept
- phase2ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- phase2Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- phase2A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
- phase3A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
- phase2Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
- phase1A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
- phase2Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
- phase1A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 8m ago
Found something off?
comments(0)
5-min edit window · permanent after that